Hemophilia A Without Inhibitors: Personalizing Therapy With Factor VIII Prophylaxis

Review multidisciplinary perspectives on leveraging clotting factor concentrates for prophylaxis of hemophilia A with downloadable slidesets from the Webcast at THSNA 2020.
Michael Callaghan, MD

ClinicalThought

Our current goals for managing hemophilia have evolved beyond simply preventing bleeding and joint damage—now, we aim to give our patients as full a life as would be possible without hemophilia. Read my take on leveraging extended half-life products and tools for estimating PK profiles to individualize hemophilia prophylaxis.

Michael Callaghan, MD Released: November 20, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Takeda Pharmaceuticals USA, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue